1-20 of 43
Annie Guerin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Pinkal Desai, Jacqueline S. Garcia, Joshua F. Zeidner, Sameem Abedin, Ofir Wolach, Pankit Vachhani, Yakir Moshe, Daniel A. Pollyea, Catherine Lai, Thomas W LeBlanc, Marin Xavier, Boaz Nachmias, Evan C. Chen, Srilakshmi Bathini, Inderpreet Bhatti, Cat N. Bui, Annie Guérin, Rebecca Burne, Esprit Ma, Moshe Grunspan, Neta Frankel, Aaron D. Goldberg
Journal: Blood
Blood (2023) 142 (Supplement 1): 5173.
https://doi.org/10.1182/blood-2023-173283
Published: 2023
Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5190.
https://doi.org/10.1182/blood-2023-180789
Published: 2023
Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5098.
https://doi.org/10.1182/blood-2023-180772
Published: 2023
Journal Articles

Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors

Srinivas K. Tantravahi, Dominick Latremouille-Viau, Raj Desai, Soyon Lee, Jincy Paulose, Lincy Geevarghese, Annie Guérin, Shravanthi Seshasayee, Nadia Tabatabaeepour, Glorian P. Yen
Journal: Blood
Blood (2023) 142 (Supplement 1): 5119.
https://doi.org/10.1182/blood-2023-180759
Published: 2023
Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C Coombs, Beenish S Manzoor, Jennifer R. Brown, Hande H. Tuncer, Chaitra S Ujjani, Lori A Leslie, Lindsey E. Roeker, Matthew S Davids, Joanna M. Rhodes, Alan Skarbnik, Nnadozie Emechebe, Isabelle Fleury, Brian T. Hill, Christopher P. Fox, Paul M. Barr, Dureshahwar Jawaid, Wendy J Sinai, Laurie K Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Stephen J. Schuster, Kaitlin Kennard, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1908.
https://doi.org/10.1182/blood-2023-179198
Published: 2023
Journal Articles

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice

Ehab L. Atallah, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Germano Ferreira, Annie Guerin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 1809.
https://doi.org/10.1182/blood-2023-178722
Published: 2023
Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Ofir Wolach, Jacqueline S. Garcia, Pinkal Desai, Pankit Vachhani, Joshua F. Zeidner, Sameem Abedin, Kendra Sweet, Catherine Lai, Yakir Moshe, Daniel A. Pollyea, Marin Xavier, Boaz Nachmias, Tsila Zuckerman, Sangmin Lee, Evan C. Chen, Srilakshmi Bathini, Wesleigh Edwards, Cat N. Bui, Wei-Han Cheng, Catherine Miller, Annie Guerin, Jessica Maitland, Esprit Ma, Melissa Montez, Moshe Grunspan, Aaron D Goldberg
Journal: Blood
Blood (2022) 140 (Supplement 1): 11026–11028.
https://doi.org/10.1182/blood-2022-159615
Published: 2022
Journal Articles

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Dandan Zheng, Kavita Sail, PhD, Lindsey E Roeker, MD, Beenish S Manzoor, PhD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Toby A. Eyre, Alan Skarbnik, MD, Rajat Bannerji, MDPhD, Barbara Eichhorst, MD, Danielle M. Brander, MD, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Rajesh Kamalakar, MS, Nnadozie Emechebe, MPH, Irina Pivneva, Rebecca Burne, Annie Guerin, MSc, Matthew S. Davids, MD, Anthony Mato, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–22.
https://doi.org/10.1182/blood-2020-134676
Published: 2020
Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment

Parameswaran Hari, MD MRCP, Lita Araujo, Dominick Latremouille-Viau, MSc, Peggy Lin, PhD, Mikhail Davidson, Annie Guerin, MSc, Medha Sasane
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-134597
Published: 2020
Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Ehab L. Atallah, MD, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Carmine Rossi, PhD, Annie Guerin, MSc, Pallavi Patwardhan, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-136074
Published: 2020
Journal Articles

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Daniel A. Pollyea, Maximilian Stahl, Chetasi Talati, MD, Hannah Asghari, MD BS, Catherine Lai, MD MPH, Sameem Abedin, MD, Joshua F. Zeidner, MD, Benyam Muluneh, PharmD, Marin Xavier, Wesleigh Edwards, MD PhD, Ofir Wolach, MD, Yakir Moshe, MDPhD, David Lavie, MD, Tsila Zuckerman, MD, Michelle Choi, Cat N. Bui, PhD, Anders Erik Svensson, MD, Steve Kye, MD MPH, Rebecca Burne, Annie Guerin, MSc, Esprit Ma, Melissa Montez, Aaron D Goldberg, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-134789
Published: 2020
Journal Articles

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Sudipto Mukherjee, MD PhD MPH, Xiting Cao, Islam Sadek, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Irina Pivneva, Annie Guérin, B. Douglas Smith, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137079
Published: 2020
Journal Articles

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Ehab L. Atallah, MD, Islam Sadek, Xiting Cao, Dominick Latremouille-Viau, Irina Pivneva, PhD, Carmine Rossi, Annie Guerin, Vamsi Kota, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2208.
https://doi.org/10.1182/blood-2019-125736
Published: 2019
Journal Articles

Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective

George J Joseph, Dominick Latremouille-Viau, Vikash Kumar Sharma, Patrick Gagnon-Sanschagrin, Menaka Bhor, PhD, Ankur Khare, Mukesh Kumar Singh, Elizabeth Serra, Mikhail Davidson, Annie Guerin, Nirmish Shah
Journal: Blood
Blood (2019) 134 (Supplement_1): 3464.
https://doi.org/10.1182/blood-2019-124920
Published: 2019
Journal Articles

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Eytan M. Stein, MD, Dominick Latremouille-Viau, George J Joseph, Sherry Shi, Annie Guerin, MSc, Eric Q Wu, Gaetano Bonifacio, Xiting Cao
Journal: Blood
Blood (2019) 134 (Supplement_1): 3495.
https://doi.org/10.1182/blood-2019-124878
Published: 2019
Journal Articles

Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study

Mazyar Shadman, MD MPH, Kavita Sail, PhD, Beenish S Manzoor, PhD, Maryam Sarraf Yazdy, MD, Brian T. Hill, MD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Nnadozie Emechebe, MPH, Rajesh Kamalakar, MS, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Thomas Marshall, PharmD, MS, Jacqueline Nielsen, PhD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Anna Schuh, PhD, Toby A. Eyre, MD, Nicole Lamanna, MD, William G. Wierda, MD PhD, Alan Skarbnik, MD, Lindsey E. Roeker, MD, Rajat Bannerji, MD PhD, James M. Pauff, MD PhD, Stephen J. Schuster, MD, George A Follows, MD PhD, Bruce D. Cheson, MD, Barbara F. Eichhorst, MD, Danielle M. Brander, MD, Irina Pivneva, PhD, Annie Guerin, MSc, Anthony R. Mato, MDMSCE
Journal: Blood
Blood (2019) 134 (Supplement_1): 3048.
https://doi.org/10.1182/blood-2019-131401
Published: 2019
Journal Articles

Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data

Raluca Ionescu-Ittu, PhD, Aijing Shang, Nancy Vander Velde, Annie Guérin, Yilu Lin, Lizheng Shi, Sherry Shi, Naseer Qayum
Journal: Blood
Blood (2018) 132 (Supplement 1): 1711.
https://doi.org/10.1182/blood-2018-99-113039
Published: 2018
Journal Articles

Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

William G Wierda, MD PhD, Genevieve Gauthier, MSc, Brian Meissner, PharmD, PhD, Annie Guerin, MS, Jennifer C. Samp, MS, PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2130.
https://doi.org/10.1182/blood.V130.Suppl_1.2130.2130
Published: 2017
Journal Articles

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Karen Seiter, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Briana Ndife, MPH, Karen Habucky, PhD, George J Joseph, BPharm, MS, PhD, Irina Pivneva, PhD, Patrick Gagnon-Sanschagrin, MS, Derek H Tang, BSPharm, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3391.
https://doi.org/10.1182/blood.V130.Suppl_1.3391.3391
Published: 2017
Journal Articles

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation

Ellen K Ritchie, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Irina Pivneva, PhD, Karen Habucky, PhD, Briana Ndife, MPH, George J Joseph, BPharm, MS, PhD, Ehab Atallah, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3396.
https://doi.org/10.1182/blood.V130.Suppl_1.3396.3396
Published: 2017